190 related articles for article (PubMed ID: 19207097)
21. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corey GR; Wilcox MH; Talbot GH; Thye D; Friedland D; Baculik T;
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv41-51. PubMed ID: 21115454
[TBL] [Abstract][Full Text] [Related]
22. Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Vidaillac C; Rybak MJ
Pharmacotherapy; 2009 May; 29(5):511-25. PubMed ID: 19397461
[TBL] [Abstract][Full Text] [Related]
23. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Wilcox MH; Corey GR; Talbot GH; Thye D; Friedland D; Baculik T;
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv53-iv65. PubMed ID: 21115455
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of ceftobiprole in the treatment of complicated skin and skin structure infections: evidence from 2 clinical trials.
Deresinski SC
Diagn Microbiol Infect Dis; 2008 May; 61(1):103-9. PubMed ID: 18384998
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
26. Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
Critchley IA; Eckburg PB; Jandourek A; Biek D; Friedland HD; Thye DA
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii45-51. PubMed ID: 21482569
[TBL] [Abstract][Full Text] [Related]
27. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
28. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
Noel GJ; Strauss RS; Amsler K; Heep M; Pypstra R; Solomkin JS
Antimicrob Agents Chemother; 2008 Jan; 52(1):37-44. PubMed ID: 17954698
[TBL] [Abstract][Full Text] [Related]
29. [Ceftaroline, a new broad-spectrum cephalosporin in the era of multiresistance].
Horcajada JP; Cantón R
Enferm Infecc Microbiol Clin; 2014 Mar; 32 Suppl 2():1-7. PubMed ID: 24702972
[TBL] [Abstract][Full Text] [Related]
30. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
DiMondi VP; Drew RH; Chen LF
Expert Rev Anti Infect Ther; 2011 Aug; 9(8):567-72. PubMed ID: 21819323
[TBL] [Abstract][Full Text] [Related]
31. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
Anderson SD; Gums JG
Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.
Merker A; Danziger LH; Rodvold KA; Glowacki RC
Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1741-50. PubMed ID: 25347329
[TBL] [Abstract][Full Text] [Related]
33. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Barbour A; Schmidt S; Rand KH; Derendorf H
Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
[TBL] [Abstract][Full Text] [Related]
34. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Saravolatz LD; Stein GE; Johnson LB
Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022
[TBL] [Abstract][Full Text] [Related]
35. New and emerging treatment of Staphylococcus aureus infections in the hospital setting.
Moreillon P
Clin Microbiol Infect; 2008 Apr; 14 Suppl 3():32-41. PubMed ID: 18318877
[TBL] [Abstract][Full Text] [Related]
36. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
37. Ceftobiprole: a new broad spectrum cephalosporin.
El Solh A
Expert Opin Pharmacother; 2009 Jul; 10(10):1675-86. PubMed ID: 19527192
[TBL] [Abstract][Full Text] [Related]
38. The problem of complicated skin and skin structure infections: the need for new agents.
Moellering RC
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv3-8. PubMed ID: 21115452
[TBL] [Abstract][Full Text] [Related]
39. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
Frampton JE
Drugs; 2013 Jul; 73(10):1067-94. PubMed ID: 23801418
[TBL] [Abstract][Full Text] [Related]
40. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.
Parish D; Scheinfeld N
Curr Opin Investig Drugs; 2008 Feb; 9(2):201-9. PubMed ID: 18246523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
